Feasibility and Preliminary Efficacy of Aerobic Acute Exercise Prior to Immunotherapy and Chemotherapy Infusion in Patients with Metastatic Non-Small Cell Lung Cancer: A Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 33 of the 41 references it cites were found in a registry or an index, and 2 are not checked yet; none of the 18 sources its claims cite is checked for support yet.
Abstract
Background/Objectives: Recent preclinical studies suggest that acute exercise induces immune modulation, enhances tumor blood perfusion, and is associated with reduced tumor growth. Adding exercise to immunochemotherapy treatment (ICT) has been proposed as a strategy to increase treatment effectiveness. The ERICA trial (NCT04676009) aimed to assess the feasibility of acute aerobic exercise performed immediately before the administration of ICT in patients with metastatic non-small cell lung cancer (mNSCLC) and to explore hypothesis-generating outcomes related to physical fitness and patient-reported outcomes. Methods: Newly diagnosed mNSCLC patients were randomly assigned (2:1) to the exercise or control group. The exercise intervention included supervised acute exercise before each of four ICT cycles plus a 3-month home-based walking program with an activity tracker and step goals. The feasibility of the exercise protocol was assessed through adherence, acceptability, tolerability, and safety. Clinical, physical, and patient-reported outcomes were assessed at baseline and after 3 months. Results: Twenty-six patients (mean age 60.6 years; SD 10.65) participated, with an 87.5% acceptance rate. In the exercise group (n = 17), 80.9% of participants completed the acute exercise sessions, with a median interval of 38 min [IQR, 20–60] between exercise and ICT. No exercise-related adverse effects were reported. After 3 months, 60% of participants in the exercise group were classified as active and maintained their step goals. Self-reported measures suggest that maintaining physical fitness is favorable for reducing fatigue and insomnia, and therefore improving quality of life. Conclusions: Acute exercise performed immediately before each ICT administration in patients with mNSCLC appears feasible and safe.
Checked 2026-10-11 · 2 references not checked yet
Overview
CoChat Summary
TL;DR
This randomized feasibility trial tested supervised aerobic exercise immediately before immunotherapy/chemotherapy infusion in patients with metastatic NSCLC and found the intervention was feasible, with high acceptance and no exercise-related adverse events. Preliminary efficacy signals were mixed: some patient-reported outcomes and activity levels improved, but physical fitness and body composition did not.
Key findings
- Of 91 screened patients, 45 were eligible (49.5%); of the 32 to whom the study was presented, 4 declined, yielding an acceptance rate of 87.5%. The final randomized sample was 26 patients: 17 in the exercise group and 9 in control.
- Adherence to the acute exercise sessions was 80.8% on average; the median number of completed sessions was 4 [IQR, 3–4], and 52.9% completed all four sessions. The median time from exercise end to ICT start was 38 min [IQR, 20–60].
- Tolerability was acceptable: exercise dose adjustments were needed for 58.8% of participants, accounting for 48.1% of sessions, and no serious exercise-related adverse events were reported.
- Preliminary effects were limited: there were no meaningful between-group differences in physical fitness at 3 months, but the exercise group’s global leisure-time physical activity score increased from 13.8 ± 14.5 to 30.9 ± 14.8. In contrast, skeletal muscle index decreased in the exercise group from 49.2 ± 6.16 to 46.2 ± 7.26 cm²/m² (p = 0.02), and control participants experienced more grade 3–4 treatment-emergent adverse events (11 grade 3 and 2 grade 4 vs 3 grade 3 and 1 grade 4 in the exercise group).
Methods
- Prospective, single-center, 2:1 randomized controlled open-label feasibility study (ERICA) conducted from January 2021 to June 2023 at the Léon Bérard Comprehensive Cancer Centre in Lyon, France.
- Included adults aged ≥18 and <80 years with metastatic NSCLC without EGFR mutation or ALK rearrangement, eligible for first-line pembrolizumab-based immunochemotherapy, with WHO performance status <2 and no contraindication to exercise.
- Intervention: supervised acute cycling exercise immediately before each of four ICT cycles, individualized to submaximal fitness, plus a 3-month home walking program targeting ≥6000 steps/day; analyses compared baseline and 3-month outcomes using nonparametric and paired tests.
Limitations
- The paper states the main limitation was the small sample size, which limited statistical power and generalizability.
- The authors also state the analyses were exploratory, unadjusted, and at risk of false positives due to multiple outcomes.
- Evident from the text: single-center design and logistical constraints affected enrollment and implementation, including 6 eligible patients not enrolled because treatment started too soon and 31% of exercise-to-infusion intervals exceeding 60 min.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
0 Valid · 0 Not valid · 13 Not checked · 61 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean global Leisure-Time PA score increased from 13.8 (±14.5) to 30.9 (±14.8) in the exercise group, with a within-group change of 15.3 (95% CI: 0.24 to 30.37).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The control group had eleven grade 3 and two grade 4 TEAEs, such as anemia, anorexia, aplasia, asthenia, neutropenia, thrombocytopenia, weight loss, diarrhea, and increased troponin I.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the acute exercise intervention combined with the home-based walking program did not significantly improve the physical fitness of participants in the exercise group at the end of the intervention, patients reported an increase in PA level, as reflected by the GLTPA score.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The exercise group experienced three grade 3 and one grade 4 treatment-emergent adverse event (TEAEs), including anemia, anorexia, and increased troponin I.”
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The exercise group maintained a median daily step count of 8550 ( SI.1 ).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 74 claims and to verify the 18 references still open.
- It may state two separate claims as one. 35
- Probably not a substantial claim. 14
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“history or risk of cardiovascular disease”
“52.2% had cardiovascular disease”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“31.6% of the control group experienced a dose reduction during ICT, whereas 19.8% of the exercise group experienced a dose reduction”
“17 to the exercise group and 9 to the control group”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“there was no attrition during the intervention period”
“The attrition rate for the exercise group was 11.8% (2/17), with no attrition in the control group.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“At 3 months, 14 participants (53.9%) achieved a partial response to treatment”
“Seven participants (28.0%) had stable disease”
Citations
Cites
CAMPBELL, K. L., WINTERS-STONE, K. M., WISKEMANN, J., MAY, A. M., SCHWARTZ, A. L., COURNEYA, K. S., ZUCKER, D. S., MATTHEWS, C. E., LIGIBEL, J. A., GERBER, L. H., et al. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002116 · Cited by 2,988 · cited 1×
“Despite American College of Sports Medicine (ACSM) recommendations for PA during cancer treatment [29], metastatic patients remain underrepresented in exercise trials [30].”
Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,680 · cited 1×
“…cut-off values < 43.0 cm 2 /m 2 for men with a BMI < 25.0 kg/m 2 , <53.0 cm 2 /m 2 for men with a BMI ≥ 25.0 kg/m 2 , and <41.0 cm 2 /m 2 for women [24]; • Patients reported outcomes (at D0, M3 and M6): health-related quality of life (EORTC QLQ C30, LC13), cancer-related fatigue (QLQ FA-12), and…”
InfluentialDesign and analysis of pilot studies: recommendations for good practice
Lancaster, G. A., Dodd, S., & Williamson, P. R. (2004) · Journal of Evaluation in Clinical Practice · doi:10.1111/j..2002.384.doc.x · Cited by 2,572 · cited 1×
“This study included 30 participants (20 in the exercise group and 10 in the control group), whose data were determined pragmatically and aligned with published recommendations [26].”
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · cited 1×
“Non-small cell lung cancer (NSCLC) represents 80 to 90% of all lung cancer cases, and more than half of all lung cancer cases are diagnosed at an advanced stage because of its paucity of symptom, resulting in poor survival rates [2,3].”
How Many Steps/Day Are Enough?: Preliminary Pedometer Indices for Public Health
Tudor-Locke, C., & Bassett, D. R. (2004) · Sports Medicine · doi:10.2165/00007256-200434010-00001 · Cited by 2,054
Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,116 · cited 2×
“Advances in treatment, particularly the combination of platinum-based chemotherapy (CT) with immune checkpoint inhibitors (ICPi) targeting programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1), have improved survival in advanced NSCLC patients [4].”
InfluentialBillingham, S. A., Whitehead, A. L., & Julious, S. A. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-104 · Cited by 962 · cited 1×
“Feasibility trials typically recommend sample sizes between 24 and 50 [25].”
Pedersen, L., Idorn, M., Olofsson, G. H., Lauenborg, B., Nookaew, I., Hansen, R. H., Johannesen, H. H., Becker, J. C., Pedersen, K. S., Dethlefsen, C., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.011 · Cited by 888 · cited 1×
“Preclinical studies further suggest that exercise-induced immune cell mobilization [15–17] and increased tumor blood perfusion during exercise are associated with reduced tumor growth [18].”
Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
Ligibel, J. A., Bohlke, K., May, A. M., Clinton, S. K., Demark-Wahnefried, W., Gilchrist, S. C., Irwin, M. L., Late, M., Mansfield, S., Marshall, T. F., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00687 · Cited by 700
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653 · cited 1×
“However, many patients exhibit primary resistance, and even initial responders often relapse due to acquired resistance [5].”
Cited by
Advanced rehabilitation approaches for patients with malignant neoplasms of the respiratory system
Kovaleva, O. V. (2026) · Реабилитология. · doi:10.17749/2949-5873/rehabil.2026.76
Physical Exercise in Immunotherapy
Johnston, C., Kim, S. J., Zhang, Y., Tsung, C., Kent, E., May, A., & Zhang, H. (2026) · Sports Medicine - Open · doi:10.1186/s40798-026-01101-1
“Similarly, the randomized ERICA trial (NCT04676009) examined the feasibility of acute aerobic exercise immediately before immunotherapy and chemotherapy infusions in patients with metastatic non-small-cell lung cancer [85].”
Funk-Debleds, P., Furness, K., Nguyen, V. V., Cardenas, D., Vansteene, D., Goldwasser, F., Alves‐Guerra, M., & Rébillard, A. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.105088
Metadata
- Authors
- Gouez, M., Pérol, O., Pialoux, V., Avrillon, V., Boussageon, M., Decroisette, C., Delrieu, L., El Hajj, H., Fournier, B., Gille, R., His, M., Mastroianni, B., Swalduz, A., Pérol, M., & Fervers, B.
- Affiliations
- Lyon 1 Université (FR)
- Inserm (FR)
- Centre Léon Bérard (FR)
- Department of Cancer Prevention and Environment, Léon Bérard Cancer Center, 69008 Lyon, France
- Department of Medical Oncology, Léon Bérard Cancer Center, 69008 Lyon, France
- Corresponding author
- Gouez, Manon
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2026-01-01
- Volume
- 15
- Issue
- 1
- Pages
- 334
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC12787285
- OpenAlex
- W7117961821
- Cited by
- 3
- References
- 41
- Citations by year
- 2026: 3
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- French Ministry of Education, Research and Innovation (Doctoral Fellowship)
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
- Keywords
- acute aerobic exercise, metastatic non-small cell lung cancer, immunotherapy, chemotherapy, chemoimmunotherapy, physical fitness, exercise adherence, fatigue, insomnia, quality of life, feasibility and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Feasibility and Preliminary Efficacy of Aerobic Acute Exercise Prior to Immunotherapy and Chemotherapy Infusion in Patients with Metastatic Non-Small Cell Lung Cancer: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.3390/jcm15010334
- The paper
- Gouez, M., Pérol, O., Pialoux, V., Avrillon, V., Boussageon, M., Decroisette, C., Delrieu, L., El Hajj, H., Fournier, B., Gille, R., His, M., Mastroianni, B., Swalduz, A., Pérol, M., & Fervers, B. (2026). Feasibility and Preliminary Efficacy of Aerobic Acute Exercise Prior to Immunotherapy and Chemotherapy Infusion in Patients with Metastatic Non-Small Cell Lung Cancer: A Randomized Controlled Trial. Journal of Clinical Medicine. https://doi.org/10.3390/jcm15010334
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.